Your SlideShare is downloading. ×
Rnrmr: Discovery Stage Partnering Terms and Agreements
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Rnrmr: Discovery Stage Partnering Terms and Agreements

68
views

Published on

Buy the report "Discovery Stage Partnering Terms and Agreements" at US $2995 for a Corporate User PDF License from RnR Market Research Reports Library.The Discovery Stage Partnering Terms and …

Buy the report "Discovery Stage Partnering Terms and Agreements" at US $2995 for a Corporate User PDF License from RnR Market Research Reports Library.The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
68
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. RnR Market Research Offers “Discovery Stage Partnering Terms and Agreements”Report at US$ 2995 Single User License. The report got published in May 2013 &Contains 1245 Pages.Rnrmarketresearch.com adds “Discovery Stage Partnering Terms and Agreements” new report on itsdatabase.The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report providescomprehensive understanding and unprecedented access to the discovery stage partnering deals andagreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter discoverystage partnering deals. The majority of deals are where the licensee obtains a right or an option right tolicense the licensors product or compound. These deals tend to be multicomponent, starting withcollaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intothe negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in termsof how payments are triggered – contract documents provide this insight where press releases do not.This report contains over 2,500 links to online copies of actual discovery stage deals and contractdocuments as submitted to the Securities Exchange Commission by companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner’s flexibilityon a wide range of important issues, many of which will have a significant impact on each party’s ability toderive value from the deal.Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=94304The report also includes numerous tables and figures that illustrate the trends and activities in discoverystage partnering and deal making since 2007.In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type,therapy focus and technology type. Each deal title links via Weblink to an online version of the deal recordand where available, the contract document, providing easy access to each contract document ondemand.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering inthe research, development and commercialization of discovery stage products and compounds.BenefitsDiscovery Stage Partnering Terms and Agreements in Pharma and Biotech provides the readerwith the following key benefits:- In-depth understanding of discovery stage deal trends since 2007- Access to headline, upfront, milestone and royalty data- Analysis of the structure of discovery stage agreements with numerous real life case studies- Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big
  • 2. biotech companies- Insight into the terms included in a discovery stage agreement, together with real world clause examples- Understand the key deal terms companies have agreed in previous deals- Undertake due diligence to assess suitability of your proposed deal terms for partner companiesReport scopeDiscovery Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech isintended to provide the reader with an in-depth understanding and access to discovery stage deal trendsand structure of deals entered into by leading companies worldwide.Discovery Stage Partnering Terms and Agreements in Pharma and Biotech includes:- Trends in discovery stage dealmaking in the biopharma industry since 2007- Analysis of discovery stage deal structure- Access to headline, upfront, milestone and royalty data- Case studies of real-life discovery stage deals- Access to over 2,500 discovery stage deals- The leading discovery stage deals by value since 2007- Most active discovery stage dealmakers since 2007- The leading discovery stage partnering resourcesBuy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=94304Table of ContentChapter 1 - IntroductionChapter 2 - Why do companies partner at discovery stage?2.1. Introduction2.2. The role of discovery stage partnering2.2.1. In-licensing at discovery stage2.2.2. Out-licensing at discovery stage2.3. Difference between discovery, preclinical and clinical stage deals2.4. Reasons for entering into discovery stage partnering deals2.4.1. Licensors reasons for entering discovery stage deals2.4.2. Licensees reasons for entering discovery stage deals2.5. The future of discovery stage partnering dealsChapter 3 - Discovery stage deal strategies and structure3.1. Introduction3.2. At what stage do companies partner?3.2.1. Partnering early in pharmaceutical/biotech3.2.1.1. Discovery and preclinical stage partnering case studies3.2.1.1.a. Case study: LEO Pharma - 4SC3.2.1.1.b. Case study: Heptares Therapeutics - Cubist3.2.1.1.c. Case study: Pfizer - Repligen3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec3.2.2. Partnering later in pharmaceutical/biotech3.2.2.1. Clinical stage partnering case studies3.2.2.1.a. Case study: Roche - Genentech - Chiasma3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals3.2.2.1.c. Case study: AstraZeneca - Ardelyx3.22.1.d. Case study: Baxter - Onconova Therapeutics3.3. Early and later stage partnering - a risk/cost comparison
  • 3. 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?3.5. Pure versus multi-component partnering deals3.6. Pure licensing agreement structure3.6.1. Example pure licensing agreements3.6.1.a. Case study : Coley Pharmaceutical - Dynavax Technologies3.6.1.b. Case study : Bristol-Myers Squibb - Pharmacopeia3.7. Multicomponent preclinical stage partnering agreements3.7.1. Example multicomponent early stage clauses3.7.1.a. Case study: Tracon - Cell Matrix - Cancervax3.7.1.b. Case study: Pfizer - InSite VisionChapter 4 - Discovery stage partnering payment strategies4.1. Introduction4.2. Discovery stage payment strategies4.3. Payment options4.3.1. Headline values4.3.2. Upfront payments4.3.2.1. Conditionality of upfront payments4.3.3. Loans4.3.4. Convertible loans4.3.5. Equity4.3.6. R&D funding4.3.7. Licensing fees4.3.8. Milestone payments4.3.9. Royalty payments4.3.9.1. Issues affecting royalty rates4.3.9.2. Royalties on combination products4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech4.3.9.3. Guaranteed minimum/maximum annual payments4.3.9.4. Royalty stacking4.3.9.5. Royalties and supply/purchase contracts4.3.10. Quids4.3.11. Option paymentsChapter 5 - Trends in discovery stage deal making5.1. Introduction5.2. Discovery stage partnering over the years5.2.1.. Attributes of discovery deals5.3. Big pharma discovery stage dealmaking activity5.4. Big biotech discovery stage dealmaking activity5.5. Discovery stage partnering by deal type5.6. Discovery stage partnering by disease type5.7. Partnering by discovery stage technology typeChapter 6 - Average payment terms for discovery stage partnering6.1. Introduction6.2. Guidelines for discovery stage payment terms6.2.1. Upfront payments6.2.2. Milestone payments6.2.3. Royalty payments6.3. Discovery stage payment terms - deal data analysis6.3.1. Public data6.3.2. Survey data6.4. Payment terms analysis6.4.1. Discovery stage headline values
  • 4. 6.4.2. Discovery stage upfront payments6.4.3. Discovery stage milestone payments6.4.4. Discovery stage royalty ratesChapter 7 - Leading preclinical stage deals7.1. Introduction7.2. Top discovery stage deals by valueChapter 8 - Big pharma and big biotech discovery stage partnering deals8.1. Introduction8.2. How to use big pharma/big biotech discovery stage partnering deals8.3. Big pharma discovery stage partnering company profilesFor more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com